Scarica l'app Stockscreener
5.83
2.02%
-0.12
Pre-mercato:
5.91
0.08
+1.37%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.95
Aprire:
$6.02
Volume 24 ore:
1.14M
Relative Volume:
1.00
Capitalizzazione di mercato:
$331.63M
Reddito:
$5.82M
Utile/perdita netta:
$71.18M
Rapporto P/E:
5.8464
EPS:
0.9972
Flusso di cassa netto:
$-84.30M
1 W Prestazione:
+8.77%
1M Prestazione:
+20.95%
6M Prestazione:
+33.72%
1 anno Prestazione:
-8.91%
Intervallo 1D:
$5.725
$6.05
Intervallo di 1 settimana:
$5.225
$6.05
Portata 52W:
$4.00
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Nome
Abeona Therapeutics Inc
Settore
Industria
Telefono
646-813-4701
Indirizzo
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.83 | 331.63M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-03-05 | Iniziato | Oppenheimer | Outperform |
| 2024-07-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-30 | Iniziato | Stifel | Buy |
| 2020-11-11 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-02-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-10 | Ripresa | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Downgrade | Maxim Group | Buy → Hold |
| 2019-08-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Downgrade | Mizuho | Buy → Neutral |
| 2019-06-27 | Iniziato | Mizuho | Buy |
| 2018-10-12 | Iniziato | Mizuho | Buy |
| 2018-06-05 | Iniziato | Seaport Global Securities | Buy |
| 2017-11-08 | Iniziato | SunTrust | Buy |
| 2017-10-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-11 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Iniziato | Citigroup | Buy |
| 2017-10-05 | Reiterato | Maxim Group | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-18 | Reiterato | Maxim Group | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-01-06 | Iniziato | Jefferies | Buy |
| 2016-09-29 | Reiterato | Maxim Group | Buy |
Mostra tutto
Abeona Therapeutics Inc Borsa (ABEO) Ultime notizie
SEC Form DEFA14A filed by Abeona Therapeutics Inc. - Quantisnow
Abeona Therapeutics® Announces Date of First Quarter Financial Results - The Manila Times
Abeona sets May 13 investor call on Q1 results and company progress - Stock Titan
2,000,000 Shares in Abeona Therapeutics Inc. $ABEO Purchased by AIGH Capital Management LLC - MarketBeat
Eight new Abeona hires get stock awards that vest over 3 years - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
AIGH, Orin Hirschman disclose 3.1M ABEO shares (ABEO) - Stock Titan
Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
[ARS] ABEONA THERAPEUTICS INC. SEC Filing - Stock Titan
Abeona Therapeutics (NASDAQ: ABEO) sets 2026 virtual meeting on directors, pay and equity plan - Stock Titan
(ABEO) Risk Channels and Responsive Allocation - Stock Traders Daily
Abeona (ABEO) Competitive Advantages | Abeona Therapeutics 2% EPS miss, $5.82M revenueRevenue Growth Rate - Xã Vĩnh Công
ABEO Should I Buy - Intellectia AI
Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor - Yahoo Finance
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 earnings call transcript - MSN
Abeona Therapeutics (NASDAQ: ABEO) asks shareholders to approve 3.1M extra equity shares - Stock Titan
Abeona Therapeutics Inc. (ABEO) Stock Analysis: Exploring a Potential 262% Upside in Biotechnology - DirectorsTalk Interviews
(ABEO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ABEO SEC FilingsAbeona Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
JPMorgan Chase Trims Stake in Abeona Therapeutics - National Today
Abeona Therapeutics Stock Price Crosses 50-Day Moving Average - National Today
JPMorgan Chase & Co. Trims Position in Abeona Therapeutics Inc. $ABEO - MarketBeat
Abeona Therapeutics (NASDAQ:ABEO) Stock Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
Aberdeen Group Invests $3.25M in Abeona Therapeutics - National Today
Aberdeen Group plc Makes New $3.25 Million Investment in Abeona Therapeutics Inc. $ABEO - MarketBeat
Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair - The Globe and Mail
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors - Sahm
Abeona Therapeutics names Keith Goldan to board of directors By Investing.com - Investing.com Canada
Abeona Therapeutics Inc. (ABEO) stock price, news, quote and history - Yahoo Finance UK
Abeona Therapeutics names Keith Goldan to board of directors - Investing.com
Abeona Therapeutics Announces Appointment of Keith A. Goldan to its Board of Directors - Bitget
Abeona Therapeutics Appoints Keith A. Goldan to Board - National Today
Abeona Therapeutics Appoints Keith A. Goldan to Board of Directors and Audit Committee to Support Commercial Growth - Minichart
[Form 4] ABEONA THERAPEUTICS INC. Insider Trading Activity - Stock Titan
Abeona Therapeutics (ABEO) director Form 3 lists no stock trades - Stock Titan
Keith A. Goldan appointed to Abeona Therapeutics' board, named Audit Committee Chair - TradingView — Track All Markets
Keith Goldan joins Abeona Therapeutics (ABEO) board as independent audit chair - Stock Titan
Biotech Abeona taps veteran CFO Keith Goldan to oversee audits - Stock Titan
Abeona Therapeutics (ABEO) — 3.01M shares disclosed by Funicular/Cable Car (5.3%) - Stock Titan
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Four new Abeona hires get stock awards vesting over 3 years - Stock Titan
Panic Selling: Should I set a stop loss on Abeona Therapeutics Inc2026 Chart Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York - Sahm
ABEO PE Ratio & Valuation, Is ABEO Overvalued - Intellectia AI
Abeona Therapeutics Inc. (ABEO) Stock Analysis: Exploring a 327% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
ABEO Technical Analysis & Stock Price Forecast - Intellectia AI
Abeona Therapeutics CEO Seshadri Vishwas sells $131k in stock By Investing.com - Investing.com Australia
Insider Sell: Vishwas Seshadri Sells 29,985 Shares of Abeona The - GuruFocus
Abeona Therapeutics CEO Seshadri Vishwas sells $131k in stock - Investing.com
Abeona Therapeutics Inc Azioni (ABEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):